ALK and non-small cell lung carcinoma: Interestingly, NSCLC patients with C797S/T790M/19Del or L858R (triple-mutation) are resistance to EGFR-TKIs, but sensitive to ALK-TKI brigatinib (Alunbrig) (Uchibori et al., 2017).